« What effective personalized medicine may look like | Main | The Republican Individual Mandate? »

04/03/2012

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Will

I saw a talk a few months ago about using metabolomics to understand the pathology of T2D and see tons of potential. I think iPOP is the clinically pertinent technology we all (or at least Topol & research grants) imagined genomic profiles could be. The idea that WHICH genes you have rather than HOW the genes are expressed was the dominant factor seems quaint in retrospect.

I also think iPOP will need to be supplemented with some type of "similar persons" graph, like CW Hogg proposed here: http://citizenmed.wordpress.com/2010/11/22/health-graph-part-2/

I worry that it is going to be hard to explain to patients in the future how personalized medicine will need a sort of "pay-in" to the system. If you don't have a year or two of metabolomic profiles on file to compare your current iPOP to, it's hard to do as much with the information (e.g., has my expression of leptin gone up or down over the last year?). Same thing with these social health graphs: you need to find similar people (whether by ethnicity, age, diet, profession or what have you) to understand what your specific risks are.

Bill Gardner

Will, thanks for a _great_ comment. "The idea that WHICH genes you have rather than HOW the genes are expressed was the dominant factor seems quaint in retrospect" gets it perfectly.

The comments to this entry are closed.

My Photo

Become a Fan